Novartis-backed Ionis subsidiary Akcea maps a $100M IPO as it steers a lead drug to regulators
Over the last three months Ionis subsidiary Akcea has executed a $1.65 billion partnership with Novartis on two of its four drugs and mapped a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
